Skip to Content

Clinical Trials

Last Updated: 2/8/2011

Untreated

Indolent Lymphoma

Intermediate/High Grade Lymphoma

  • R-HCVAD alternating with /R-Methotrexate-Cytarabine vs R-CHOP (2005-0054)
  • RAD001 (2009-0793)

Hodgkin's Lymphoma

Mantle Cell Lymphoma

  • Bortezomib + R-HyperCVAD alternating with Bortezomib+ R-High dose Methotrexate/Cytarabine (2006-0697)

Peripheral T-Cell Lymphoma

Multiple Myeloma/Waldenstrom’s

  • Bortezomib, CNTO328, Melphalan, Prednisone (2009-0113)
  • Bortezomib, Lenalidomide, Dexamethasone, Vorinostat (2008-0794)
  • Bortezomib, Lenalidomide, Dexamethasone (SWOG SO0777)

Prior Treatment

Indolent Lymphoma

Intermediate Grade Lymphoma

Hodgkin's Lymphoma

Mantle Cell Lymphoma

Peripheral T-cell Lymphoma

Multiple Myeloma/Waldenstrom's

Phase I Agents

Supportive Care

WaldenstrÖm's Macroglobulinemia

Patients Who Previously Received Post Allo Transplant


© 2013 The University of Texas MD Anderson Cancer Center